OncoLink Cancer Treatment and Resources

Utility of 18-FDG-PET Scanning in Lymphoma by WHO Classification



Reviewer: M. Kara Bucci, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: December 8, 2001

Presenter: Rebecca L. Elstrom

Background:

18-FDG-PET scanning is an important imaging modality in the staging and monitoring of many malignancies, including lymphoma. Some tumors, however, do not have the high glucose uptake needed for 18-FDG uptake, and are therefore not well imaged by PET. In order to assess whether the histologic subtype of a lymphoma is related to its visibility by PET imaging, this retrospective analysis of PET scans was performed at the University of Pennsylvania. The author's assessed PET positivity of newly diagnosed and untreated relapsed lymphoma by WHO classification of the tumors.

Materials and Methods

  • Of >600 PET scans performed on patients with lymphoma, 155 cases had pathologic data available for correlation.
  • By histologic subtype of these 155:
  • 48 diffuse large B-cell lymphomas (LBCL)
    37 follicular lymphomas (FL)
    40 Hodgkin's lymphomas (HL)
    12 marginal zone lymphomas (MZL)
    7 mantle cell lymphomas (MCL)
    2 cutaneous B-cell lymphomas (CBCL)
    2 anaplastic large T-cell lymphomas (ALCL)
    4 peripheral T-cell lymphomas (PTCL)
    1 mycosis fungoides (MF)
    1 Burkitt-like lymphoma (BLL)

Results:

  • Overall, 144/155 (93%) scans were positive.
  • PET imaging was considered "informative" in all 144 cases with positive scans.
  • By histologic subtype:
    • 100% of CBCL, FL, MCL, ALCL, BLL, and MF cases showed increased 18-FDG uptake.
    • 40/41 (98%) HD, 7/12 (58%) MZL, 1/4 (25%) PTCL, and 0/2 (0%) CBCL cases demonstrated increased 18-FDG uptake.
    • 100% of low grade lymphomas (FL, MCL) were PET-positive.

Author's conclusions:

  • For the most common histologic subtypes (LBCL, FL, HD, MCL), PET scanning was informative.
  • For less common lyphoma subtypes (PTCL, MZL, CBCL) PET scanning was less reliable.
  • The abnormal metabolism of glucose that leads to a positive PET scan may not be part of the malignant transformation of the non-reliably PET-positive lymphomas.
  • Histologic grade (as opposed to WHO subtype) may not be the most important factor determining PET-positivity.

Clinical/Scientific Implications:

  • PET is emerging as an important imaging modality in lymphoma, and may be more often indicated in the histologic subtypes that are reliable PET-positive.
  • Studies evaluating the role of altered glucose metabolism in malignancy are underway.

OncoLink I wish u knew...

Dr. Vapiwala discusses the public awareness of prostate cancer and the public support for the disease. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS